Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

ConditionsCoronary Artery Disease Ischemic Mitral Regurgitation Angiotensin Receptor/Neprilysin Inhibitor

Trial statusRecruiting

Trial phasePhase 4

Trial typeInterventional

Biological sexAll

Age18+

SponsorChina National Center for Cardiovascular Diseases

About this trial

This study aims to evaluate the effect of angiotensin receptor/neprilysin inhibitors (ARNI) on improving ischemic mitral regurgitation (IMR) in patients with coronary artery disease undergoing isolated coronary artery bypass grafting (CABG) through a randomized controlled clincial trial.

Eligibility criteria

Qualifiers

Fully informed and voluntarily signed informed consent;

Received CABG and moderate IMR was diagnosed on two consecutive preoperative transthoracic echocardiography (according to 2021 ESC/EACTS Guidance Standards )

Disqualifiers

None

Trial design

Treatments tested in this trial

sacubitril/valsartan

Treatment groups

220 Participants

are divided into 2 treatment groups

Sponsors and collaborators

China National Center for Cardiovascular Diseases

Lead sponsor

Chinese Academy of Medical Sciences, Fuwai Hospital

Collaborator

Chinese Academy of Medical Sciences

Collaborator

Source ClinicalTrials.gov